Evidence map›Paper›PMID 36535118›Full record

ReviewThe Journal of surgical research2023

Innovative Imaging Techniques Used to Evaluate Borderline-Resectable Pancreatic Adenocarcinoma.

Hunter Chalfant, Morgan Bonds, Kristina Scott, Anna Condacse, Isabel S Dennahy, W Taylor Martin, Cooper Little, Barish H Edil, Lacey R McNally, Ajay Jain

Open access · greenAbstract readReview
In one paragraph

Review in The Journal of surgical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Assessment of Breast Tumors Using Multispectral Optoacoustic Tomography in a Surgical Setting.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Trial
  2. Review
  3. Review
  4. Review
  5. Theranostic nanoparticles for detection and treatment of pancreatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hunter ChalfantDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Morgan BondsDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Kristina ScottDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Anna CondacseDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Isabel S DennahyDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
W Taylor MartinDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Cooper LittleDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Barish H EdilDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
Lacey R McNallyDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma. Electronic address: lacey_mcnally@hotmail.com.
Ajay JainDepartment of Surgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma. Electronic address: Ajay-jain@ouhsc.edu.
University of Oklahoma Health Sciences Center · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
Stroma Targeted Theranostic Nanoparticles for Pancreatic CancerR01CA212350 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2017 to 2021
$1.7M
Non-Invasive Detection of Tumor Extracellular pH using Multispectral Optoacoustic TomographyR01CA205941 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2016 to 2021
$1.7M
Theranostic Nanoparticles For Detection and Treatment of Pancreatic CancerR01EB020125 · NIBIB · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCNALLY, LACEY R · 2016 to 2019
$1.7M
NCI NIH HHS P30 CA225520NCI NIH HHS R01 CA205941NCI NIH HHS R01 CA212350NIBIB NIH HHS R01 EB020125
6 · The paper itself

Abstract

A diagnosis of pancreatic cancer carries a 5-y survival rate of less than 10%. Furthermore, the detection of pancreatic cancer occurs most often in later stages of the disease due to its location in the retroperitoneum and lack of symptoms (in most cases) until tumors become more advanced. Once diagnosed, cross-sectional imaging techniques are heavily utilized to determine the tumor stage and the potential for surgical resection. However, a major determinant of resectability is the extent of local vascular involvement of the mesenteric vessels and critical tributaries; current imaging techniques have limited capacity to accurately determine vascular involvement. Surrounding inflammation and fibrosis can be difficult to discriminate from viable tumor, making determination of the degree of vascular involvement unreliable. New innovations in fluorescence and optoacoustic imaging techniques may overcome these limitations and make determination of resectability more accurate. These imaging modalities are able to more clearly discern between viable tumor tissue and non-neoplastic inflammation or desmoplasia, allowing clinicians to more reliably characterize vascular involvement and develop individualized treatment plans for patients. This review will discuss the current imaging techniques used to diagnose pancreatic cancer, the barriers that current techniques raise to accurate staging, and novel fluorescence and optoacoustic imaging techniques that may provide more accurate clinical staging of pancreatic cancer.

Indexed as

AdenocarcinomaPancreatic NeoplasmsDiagnostic ImagingHumansNeoplasm StagingPancreatectomyFluorescenceImage-guided surgeryOptoacoustic imagingPancreatic cancerResectability

Identifiers

PMID36535118
PMCPMC10131671
OpenAlexW4311818139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.